Sökning: id:"swepub:oai:lup.lub.lu.se:ab57ab32-698c-41f9-bebf-afc840a55ed2" >
Individualizing The...
-
Smith, Robert
(författare)
Individualizing Therapies in Type 2 Diabetes Mellitus Based on Patient Characteristics: What We Know and What We Need to Know.
- Artikel/kapitelEngelska2010
Förlag, utgivningsår, omfång ...
-
The Endocrine Society,2010
Nummerbeteckningar
-
LIBRIS-ID:oai:lup.lub.lu.se:ab57ab32-698c-41f9-bebf-afc840a55ed2
-
https://lup.lub.lu.se/record/1582643URI
-
https://doi.org/10.1210/jc.2009-1966DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:art swepub-publicationtype
-
Ämneskategori:ref swepub-contenttype
Anmärkningar
-
Objective: Type 2 diabetes is heterogeneous in its clinical features, pathogenesis, and predisposing or causal genetic factors. This report examines what is known and what needs to be learned about the potential to individualize glycemic therapies in type 2 diabetes, based on phenotypes and genotypes. Participants: A 29-member international working group with expertise in diabetes epidemiology, physiology, genetics, clinical trials, and clinical care participated in formal presentations and discussions at a conference on April 16-17, 2009. A writing group subsequently prepared this summary and recommendations. The conference was coendorsed by The Endocrine Society and the American Diabetes Association and was supported by an unrestricted educational grant from Novo Nordisk. Evidence: Participants reviewed and discussed published literature, plus their own unpublished data. Consensus Process: The summary and recommendations were supported unanimously by the writing group as representing the majority or unanimous opinions of the working group. Conclusions: Recent advances in genetics, such as the identification of Kir6.2 mutations and the responsible genes for several forms of maturity onset diabetes of the young (MODY), have established precedents linking specifically effective therapies to defined diabetes subtypes. The recent increase in identified polygenic factors related to type 2 diabetes and our understanding of the pathogenesis of diabetes provide potential opportunities to individualize therapy. To further this process, we recommend expanded analysis of existing data sources and the development of new basic and clinical research studies, including a greater focus on identifying type 2 diabetes subtypes, their response to different therapies, and quantitation of cost-effectiveness.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Nathan, David M
(författare)
-
Arslanian, Silva A
(författare)
-
Groop, LeifLund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups(Swepub:lu)endo-lgr
(författare)
-
Rizza, Robert A
(författare)
-
Rotter, Jerome I
(författare)
-
Genomik, diabetes och endokrinologiForskargrupper vid Lunds universitet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:The Journal of clinical endocrinology and metabolism: The Endocrine SocietyApr 7, s. 1566-15741945-71970021-972X
Internetlänk
Hitta via bibliotek
Till lärosätets databas